Business development

At Cantargia, we are working on breakthrough therapies in immunology and oncology, derived from our robust scientific CANxx platform and supported by a strong IP portfolio. With promising clinical and preclinical data obtained in our programs, we aim to address unmet medical needs and significantly improve patient outcomes.

A key component to deliver on Cantargia’s strategy is to establish partnerships through collaboration agreements with leading pharmaceutical and biotech companies as well as with world-class research institutes. Through our collaboration on the CAN10 program with Otsuka Pharmaceutical – a global Japanese pharma company – we gain not only financial support but also access to world-class expertise in drug development, manufacturing, and commercialization.

The partnership around this development program, is a strong validation of the scientific quality of Cantargia’s research & development activities as well as our ability to attract global industry leaders. Strategic collaborations of this kind enhance our capacity to bring innovative therapies all the way to patients.

Looking ahead, additional agreements may provide further funding as well as complementary capabilities in preclinical and clinical development, manufacturing, marketing, global reach, and other resources. Close collaborations with academic institutions, such as MD Anderson Cancer Center, are also a cornerstone of our research strategy. Cantargia currently works with leading scientists at several of the world’s top universities.

We welcome conversations with organizations interested in collaborating with us and we are eager to explore how we can create lasting value together.